The Board of Directors decided in its meeting on March 6, 2008, to
submit a proposal to the Ordinary General Meeting on April 21, 2008,
to pay a dividend of EUR 0.30 per share for the fiscal year 2007. This
proposal is based on the underlying earnings per share of
EUR 1.55 achieved in fiscal 2007. For fiscal 2006, the dividend
payment of former Stedim S.A. was EUR 0.19 per share.
Furthermore, the Board of Directors decided that Ms. Liliane de
Lassus (64), Vice CEO and Member of the Board of the company, will
change from her executive position to the position of a non-executive
Director, effective
April 1, 2008.
Current image files:
Sartorius Stedim Biotech:
www.sartorius-stedim.com/media/content/
press/support/Fluid_Management.jpg
Joachim Kreuzburg,
CEO and Chairman of the Board of Sartorius Stedim Biotech S.A.
www.sartorius-stedim.com/media/content/
press/support/Dr_Kreuzburg.jpg
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech (Paris:DIM) is a leading provider of
cutting-edge equipment and services for the development, quality
assurance and production processes of the biopharmaceutical industry.
Its integrated solutions covering fermentation, filtration,
purification, fluid management and lab technologies are supporting the
biopharmaceutical industry around the world to develop and produce
drugs safely, timely and economically. For next generation processes,
Sartorius Stedim Biotech focuses on single-use technologies and
added-value services to meet the rapidly changing technology
requirements of the industry it serves. Strongly rooted in the
scientific community and closely allied with customers and technology
partners, the company is dedicated to its philosophy of "Turning
science into solutions."
Headquartered in Aubagne, France, Sartorius Stedim Biotech is
listed on the Eurolist of Euronext Paris. With its own manufacturing
and sales companies in Europe, North America and Asia, Sartorius
Stedim Biotech enjoys a worldwide presence. Its key manufacturing and
R&D location is in Germany. The company employs over 2,300 people, and
achieved for 2007 pro forma sales revenue of 375.9 million euros.
